Optimal treatment of pyoderma gangrenosum

American Journal of Clinical Dermatology

Volumn 4, Issue 9, 2003, Pages 597-608

  Gettler, Samuel L ^a   Rothe, Marti J ^a,b   Grin, Caron ^a   Grant Kels, Jane M ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; BROMOCRIPTINE; CARBAMAZEPINE; CHLORAMBUCIL; CHLORMETHINE; CIMETIDINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DAPSONE; DAUNORUBICIN; IMMUNOSUPPRESSIVE AGENT; MELPHALAN; MESALAZINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RANITIDINE; SALAZOSULFAPYRIDINE; SULFAPYRIDINE; TACROLIMUS; TRIAMCINOLONE; UNINDEXED DRUG;

ABDOMINAL PAIN; AMEBIASIS; ANTIBODY DETECTION; ANTIINFLAMMATORY ACTIVITY; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BACTERIUM CULTURE; BULLOUS SKIN DISEASE; CROHN DISEASE; DEBRIDEMENT; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DOPPLER FLOWMETRY; DRUG EFFICACY; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FACTITIOUS DISEASE; FUNGUS CULTURE; GINGIVA HYPERPLASIA; HEMATOLOGIC MALIGNANCY; HISTOPATHOLOGY; HUMAN; HYPERBARIC OXYGEN; HYPERLIPIDEMIA; HYPERTENSION; IDIOPATHIC DISEASE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INSECT BITE; KIDNEY DYSFUNCTION; LEG CRAMP; LOCAL THERAPY; NEOPLASM; PARESTHESIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUSTULE; PYODERMA GANGRENOSUM; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN BIOPSY; SKIN GRANULOMA; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT INDICATION; TREMOR; VASCULAR DISEASE; VENEREAL DISEASE REACTION TEST; WOUND CARE;

ADJUVANTS, IMMUNOLOGIC; ADRENAL CORTEX HORMONES; ANTI-INFECTIVE AGENTS; COMBINED MODALITY THERAPY; DECISION TREES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PRACTICE GUIDELINES; PYODERMA GANGRENOSUM;

EID: 0042236643     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304090-00002     Document Type: Article

References (72)

1. Brocq L. Nouvelle contribution a l'etude du phagedenisme geometrique. Ann Dermatol Syphiligr (Paris) 1916; 6: 1-39
2. Brunsting LA, Goeckerman WH, O'Leary PA. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occurring in adults. Arch Dermatol Syphilol 1930; 22: 655-80
3. Bennett ML, Jackson JM, Jorizzo JL, et al. Pyoderma gangrenosum: a comparison of typical and atypical forms with an emphasis on time to remission: case review of 86 patients from 2 institutions. Medicine 2000; 79 (1): 37-46
4. Powell FC, Su WPD, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996; 34 (3): 395-409
5. Lachapelle JM, Marot L, Jablonska S. Superficial granulomatous pyoderma gangrenosum of the face, successfully treated by ciclosporine: a long-term follow-up. Dermatology 2001; 202: 155-7
6. Von Den Driesch P. Pyoderma gangrenosum: a report of 44 cases with follow-up. Br J Dermatol 1997; 137: 1000-5
7. de Imus G, Golomb C, Wilkel C, et al. Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol 2001; 44 (1): 61-6
8. Phillips TJ, Bigby M, Bercovitch L. Cultured allografts as an adjunct to the medical treatment of problematic leg ulcers. Arch Dermatol 1991; 127: 799-801
9. Goldstein F, Krain R, Thornton JJ. Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol 1985; 7: 499-501
10. Gardner LW, Acker DW. Triamcinolone and pyoderma gangrenosum. Arch Dermatol 1972; 106: 599-600
11. Tamir A, Landau M, Brenner S. Topical treatment with 1% sodium cromoglycolate in pyoderma gangrenosum. Dermatology 1996; 192 (3): 252-4
12. Tsele E, Yu RCH, Chu AC. Pyoderma gangrenosum: response to topical nitrogen mustard. Clin Exp Dermatol 1992; 17: 437-40
13. Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139: 738-59
14. Sanders CJG, Hulsmans RFHJ. Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Curtis 1993; 51 (4): 262-4
15. Chow RKP, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34: 1047-60
16. Thomas CY, Crouch JA, Guastello J. Hyperbaric oxygen therapy for pyoderma gangrenosum. Arch Dermatol 1974; 110: 445-6
17. Davis JC, Landeen JM, Levine RA. Pyoderma gangrenosum: skin grafting after preparation with hyperbaric oxygen. Plastic Reconstr Surg 1987; 79: 200-6
18. Reynoso-von Drateln C, Perla-Navarro AV, Gamez-Nava JI, et al. Intravenous cyclophosphamide in pyoderma gangrenosum: an open trial. J Rheumatol 1997; 24 (4): 689-93
19. Johnson RB, Lazarus GS. Pulse therapy: therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982; 118: 76-84
20. Sabir S, Werth VP. Pulse glucocorticoids. Dermatol Clin 2000; 18 (3): 437-46
21. White KP, Driscoll MS, Rothe MJ, et al. Severe adverse cardiovascular effects of pulse steroid therapy: is continuous cardiac monitoring necessary? J Am Acad Dermatol 1994; 30 (5 Pt 1): 768-73
22. Cather JC, Abramovits W, Menter A. Cyclosporine and tacrolimus in dermatology. Dermatol Clin 2001; 19 (1): 119-37
23. Matis WL, Ellis CN, Griffiths CEM. et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128: 1060-4
24. Curley RK, Macfarlane AW, Vickers CFH. Pyoderma gangrenosum treated with cyclosporin A. Br J Dermatol 1985; 113: 601-4
25. Kauvar AB, Stiller MJ. Cyclosporine in dermatology: pharmacology and clinical use. Int J Dermatol 1994; 33 (2): 86-96
26. Lebwohl M, Ellis C, Gottlieb A, et al. Cyclosporine consensus conference: with emphasis on the treatment of psoriasis. J Am Acad Dermatol 1998; 39 (3): 464-75
27. Wolverton SE. Comprehensive dermatologic drug therapy. Philadelphia: WB Saunders, 2001
28. Eichhornn PJ. Pyoderma gangrenosum. Dermatol Ther 2001; 14: 102-10
29. Shapiro LE, Knowles SR, Shear NH. Comparative safety of tetracycline, minocycline, and doxycycline. Arch Dermatol 1997; 133: 1224-30
30. Wolverton SE, Wilkin JK. Systemic drugs for skin diseases. Philadelphia: WB Saunders, 1991
31. Remicade® (infiiximab) for IV injection. Physician's Desk Reference. 57th edition. Montvale (NJ): Thomson PDR, 2003: 1178-82
32. Weichert G, Sauder DN. Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum. J Am Acad Dermatol 1998; 39 (4): 648-50
33. Abu-Elmagd K, Van Thiel DH, Jegasothy BV, et al. Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med 1993; 119 (7 Pt 1): 595-8
34. Lyon CC, Kirby B, Griffiths CEM. Recalcitrant pyoderma gangrenosum treated with systemic tacrolimus. Br J Dermatol 1999; 140: 538-68
35. Hohenleutner U, Mohr VD, Michel S, et al. Mycophenolate mofetil and cyclosporine treatment for recalcitrant pyoderma gangrenosum [letter]. Lancet 1997; 350 (9053): 1748
36. Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000 Sep 27; 284 (12): 1546-8
37. Kitchin JES, Pomeranz MK, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanisms, side effects, and potential uses. J Am Acad Dermatol 1997; 37 (3): 445-9
38. Nousari HC, Lynch W, Anhalt GJ, et al. The effectiveness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol 1998; 134 (12): 1509-11
39. Grandmann-Kollmann M, Podda M, Oschsendorf F, et al. Mycophenolate mofetil is effective in the treatment of atopic dermatitis. Arch Dermatol 2001 Jul; 137 (7): 870-3
40. Dutz JP, Ho VC. Immunosuppressive agents in dermatology: an update. Dermatol Clin 1998 Apr; 16 (2): 235-51
41. Byrne JPH, Hewitt M, Summerly R. Pyoderma gangrenosum associated with active chronic hepatitis. Arch Dermatol 1976; 112: 1297-301
42. Knowles SR, Gupta AK, Shear NH, et al. Azathioprine hypersensitivity-like reactions: a case report and review of the literature. Clin Exp Dermatol 1995; 20: 353-6
43. Tavadia SMB, Mydlarski PR, Reis MD, et al. Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case. J Am Acad Dermatol 2000; 42 (4): 628-32
44. Teitel AD. Treatment of pyoderma gangrenosum with methotrexate. Cutis 1996; 57 (5): 326-8
45. Zonana-Nacach A, Jimenez-Balderas FJ, Martinez-Osuna P, et al. Intravenous cyclophosphamide pulses in the treatment of pyoderma gangrenosum associated with rheumatoid arthritis: report of 2 cases and review of the literature. J Rheumatol 1994; 21: 1352-6
46. Fox LP, Pandya AG. Pulse intravenous cyclophosphamide therapy for dermatologic disorders. Dermatol Clin 2000; 18: 459-73
47. Burruss JB, Farmer ER, Callen JP. Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 1996; 35 (5): 720-4
48. Resnick BI, Rendon M, Kerdel FA. Successful treatment of aggressive pyoderma gangrenosum with pulse steroids and chlorambucil. J Am Acad Dermatol 1992; 27: 635-6
49. Moller H, Waldenstrom JG, Zettervall O. Pyoderma gangrenosum (dermatitis ulcerosa) and monoclonal (IgA) globulin healed after melphelan treatment: case report and review of the literature. Acta Med Scand 1978; 203: 293-6
50. Perry, HO, Brunsting LA. Pyoderma gangrenosum: a clinical study of 19 cases. Arch Dermatol 1957; 75: 380-6
51. Lorincz AL, Pearson RW. Sulfapyridine and sulfone type drugs in dermatology. Arch Dermatol 1962; 85: 42-54
52. Paniker U, Levine N. Dapsone and sulfapyridine. Dermatol Clin 2001; 19: 79-86
53. Lynch WS, Bergfeld WF. Pyoderma gangrenosum responsive to minocycline hydrochloride. Cutis 1978; 21: 535-8
54. Galun E, Flugelman MY, Rachmilewitz D. Pyoderma gangrenosum complicating ulcerative colitis: successful treatment with methylprednisolone pulse therapy and dapsone. Am J Gastroenterol 1986; 81: 988-9
55. Michaelsson G, Molin L, Ohman S, et al. Clofazimine: a new agent for the treatment of pyoderma gangrenosum. Arch Dermatol 1976; 112: 344-9
56. Kaplan B, Trau H, Sofer E, et al. Treatment of pyoderma gangrenosum with clofazimine. Int J Dermatol 1992; 31 (8): 591-3
57. Boulinguez S, Bernard P, Bedane C, et al. Pyoderma gangrenosum complicating Cogan's syndrome. Clin Exp Dermatol 1998; 23: 286-9
58. Sullivan TP, King LE, Boyd AS. Colchicine in dermatology. J Am Acad Dermatol 1998; 39 (6): 993-9
59. Lugassy G, Ronnen M. Case report: severe pyoderma gangrenosum associated with familial mediterranean fever-favorable response to colchicine in three patients. Am J Med Sci 1992; 304: 29-31
60. Hecker MS, Lebwohl MG. Recalcitrant pyoderma gangrenosum: treatment with thalidomide. J Am Acad Dermatol 1998; 38 (3): 490-1
61. Buckley C, Sarkany I, Bayoum AHM. Pyoderma gangrenosum with severe pharyngeal ulceration. J R Soc Med 1990; 83: 590-1
62. Radomsky CL, Levine N. Thalidomide. Dermatol Clin 2001; 19: 87-103
63. System for thalidomide education and prescribing: safety instructions for prescribers. Celgene Corporation, 1998
64. Dirschka T, Kastner U, Behrens S, et al. Successful treatment of pyoderma gangrenosum with intravenous human immunoglobulin. J Am Acad Dermatol 1998; 39 (5): 789-90
65. Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 1995; 32: 140-2
66. Rutter A, Luger TA. High-dose intravenous immunoglobulins: an approach to treat severe immune-mediated and autoimmune diseases of the skin. J Am Acad Dermatol 2001; 44 (6): 1010-24
67. Smith JB, Shenefelt PD, Soto O, et al. Pyoderma gangrenosum in a patient with cryoglobulinemia and hepatitis C successfully treated with interferon alfa. J Am Acad Dermatol 1996; 34 (5): 901-3
68. Tan MH, Gordon M, Lebwohl O, et al. Improvement of pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alfa monoclonal antibody. Arch Dermatol 2001; 137: 930-3
69. Mimouni D, Anhalt GJ, Kouba DJ, et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003; 148: 813-6
70. Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with Crohn disease: effect of TNF-α blockade with infliximab. Scand J Gastroenterol 2002; 37: 1108-10
71. Triantafillidis JK, Cheracakis P, Sklavaina M, et al. Favorable reponse to infliximab treatment in a patient with Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 2002; 37: 863-5
72. Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroid-resistant pyoderma gangrenosum associated Crohn's disease: rapid cure with infliximab. Dermatology 2002; 205: 278-80